Sunzen Biotech Bhd
is on track to break even this year and aims to achieve profitability in 2022, after incurring losses for three years, according to group managing director and CEO Teo Yek Ming.
Teo tells StarBizWeek that in the near term, the group is optimistic about growing profits for its traditional Chinese medicine, herbal health foods and beverages and bird’s nest segment as well as the recently acquired small and medium enterprise loan financing unit.
